PD-L1 over-expression and survival in patients with non-small cell lung cancer: a meta-analysis

被引：74

作者：

Zhou, Ze-Jun ^{[1
]}

Zhan, Ping ^{[1
]}

Song, Yong ^{[1
]}

机构：

[1] Nanjing Univ, Jinling Hosp, Sch Med, Dept Resp Med, 305 East Zhongshan Rd, Nanjing 210002, Jiangsu, Peoples R China

来源：

TRANSLATIONAL LUNG CANCER RESEARCH | 2015年 / 4卷 / 02期

关键词：

Programmed cell death-ligand 1 (PD-L1); prognosis; lung cancer; meta-analysis;

D O I：

10.3978/j.issn.2218-6751.2015.03.02

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background: Observational studies on the prognostic role of programmed cell death-ligand 1 (PD-L1) in non-small cell lung cancer (NSCLC) are controversial. Methods: To clarify the impact of PD-L1 in NSCLC survival, we performed this meta-analysis that included eligible studies. The combined hazard ratios (HR) and their corresponding 95% confidence intervals (CIs) were calculated in terms of overall survival. Results: A total of five studies with 877 patients were evaluable for this meta-analysis. Our results suggested that PD-L1 overexpression had a poor impact on survival of patients with NSCLC, the HR (95% CI) was 1.43 (1.24-1.63) overall, 1.51 (1.24-1.7954) in Asian patients, 1.35 (1.08-1.63) in non-Asian patients. Moreover, there was no heterogeneity between the studies. Conclusions: PD-L1 overexpression indicates a poor prognosis for patients with NSCLC.

引用

页码：203 / 208

页数：6

共 42 条

[1]

Jemal A., Siegel R., Xu J., Et al., Cancer statistics, 2010, CA Cancer J Clin, 60, pp. 277-300, (2010)

[2]

Molina J.R., Yang P., Cassivi S.D., Et al., Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship, Mayo Clin Proc, 83, pp. 584-594, (2008)

[3]

Alberg A.J., Ford J.G., Samet J.M., Et al., Epidemiology of lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition), Chest, 132, pp. 29S-55S, (2007)

[4]

Paesmans M., Sculier J.P., Libert P., Et al., Prognostic factors for survival in advanced non-small-cell lung cancer: univariate and multivariate analyses including recursive partitioning and amalgamation algorithms in 1, 052 patients. The European Lung Cancer Working Party, J Clin Oncol, 13, pp. 1221-1230, (1995)

[5]

Donnem T., Bremnes R.M., Busund L.T., Et al., Gene expression assays as prognostic and predictive markers in early stage non-small cell lung cancer, J Thorac Dis, 4, pp. 212-213, (2012)

[6]

Osarogiagbon R.U., Predicting survival of patients with resectable non-small cell lung cancer: Beyond TNM, J Thorac Dis, 4, pp. 214-216, (2012)

[7]

Dong H., Zhu G., Tamada K., Et al., B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion, Nat Med, 5, pp. 1365-1369, (1999)

[8]

Creelan B.C., Update on immune checkpoint inhibitors in lung cancer, Cancer Control, 21, pp. 80-89, (2014)

[9]

Yamazaki T., Akiba H., Iwai H., Et al., Expression of programmed death 1 ligands by murine T cells and APC, J Immunol, 169, pp. 5538-5545, (2002)

[10]

Zou W., Chen L., Inhibitory B7-family molecules in the tumour microenvironment, Nat Rev Immunol, 8, pp. 467-477, (2008)

← 1 2 3 4 5 →